Maintenance. We are currently updating the site. Please check back shortly
Members login
  • TrustLaw
  • Members Portal

Carmat artificial heart patient in good condition -hospital

Source: Reuters - Mon, 30 Dec 2013 01:59 PM
Author: Reuters
Tweet Recommend Google + LinkedIn Bookmark Email Print
Leave us a comment

(Repeats to additional Reuters clients)

* Hospital team says patient's condition very satisfactory

* Carmat declines to comment at early stage of trial

* Hospital to give fresh update in one week

* Carmat shares up 4 pct in strong volumes (Adds details, shares, Carmat no comment)

By Natalie Huet

PARIS, Dec 30 (Reuters) - French artificial heart maker Carmat's first patient is in a "very satisfactory condition" 12 days after being fitted with the device, the hospital treating him said on Monday.

The 75-year-old Frenchman is eating normally and spent three hours sitting in a chair in the company of his family on Sunday, the team caring for him at the Georges Pompidou European Hospital in Paris said.

"The artificial heart is functioning normally, automatically catering to the body's needs without any manual adjustment necessary," surgeons Alain Carpentier and Christian Latremouille said in a statement issued by the hospital.

Three more patients in France are due to be fitted with the device. In this first series of clinical studies, its success will be judged on whether patients survive with the implant for at least a month.

The people selected suffer from terminal heart failure - when the sick heart can no longer pump enough blood to sustain the body - and would otherwise have only a few days or weeks to live.

The hospital said it would give another update on the first patient in one week. A spokeswoman for Carmat said the company declined to comment at such an early stage in the trial.

Heart-assistance devices have been used for decades as a temporary solution for patients awaiting transplants, but Carmat's bioprosthetic product is designed to replace the real heart over the long term, mimicking nature using biological materials and sensors.

It aims to extend life for patients suffering from terminal heart failure who cannot hope for a heart transplant, often because they are too old and donors too scarce.

Carmat shares were 4.2 percent higher at 112.39 euros at 1308 GMT, trading in volumes more than twice the daily average of the past three months. (Additional reporting by Alexandre Boksenbaum-Granier; Editing by James Regan)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus

Latest slideshow

See allSee all
Featured jobs